强化他汀降脂与传统降脂治疗进展性脑卒中的对比研究

Comparative study of cholesterol-lowing effect between intensive statin therapy and traditional treatment in patients with progressive stroke

目的对进展性脑卒中患者采用强化他汀治疗与传统降脂治疗行疗效对比研究,探讨强化治疗方案的临床应用价值。方法收集我院2013-09—2014-07收治的120例进展性脑卒中患者,随机分为对照组和观察组各60例。对照组予氟伐他汀钠缓释片40mg/d(常规降脂治疗),观察组予氟伐他汀钠缓释片80mg/d(强化降脂治疗),2周后观察血脂变化与临床疗效,比较2组治疗前后的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)与高密度脂蛋白胆固醇(HDL-C)水平及NIHSS评分。结果治疗前2组血脂水平无显著性差异,治疗后TC、LDL-C水平均显著降低(P<0.05),HDL-C的表达水平则显著升高。与对照组相比,观察组疗效更明显,NIHSS评分降低幅度更大(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论进展性脑卒中患者采用强化他汀方案治疗安全有效,有较高临床应用价值。

Objective To compare the effect of cholesterol-lowing therapy between intensive statin medication and traditional treatment in patients with progressive stroke in order to explore the clinical application value of the intensive treatment.Methods A total of 120 patients with progressive stroke in our hospital from September 2013 to July 2014 were enrolled and randomly divided into two groups,60 patients in each group.All patients given cholesterol-lowing treatment of fluvastatin sustained-release tablets,control group received the traditional dosage of 40mg/d while observation group received intensive treatment of 80mg/d fluvastatin.After two weeks,the levels of total cholesterol（TC）,low-density lipoprotein cholesterol（LDL-C）,high-density lipoprotein cholesterol（HDL-C）and NIHSS scores were comparatively analyzed between two groups to observe the change of blood lipids and assess the clinical efficacy.Results Before treatment,there were no significant differences in levels of blood lipid of two groups.After treatment,the levels of TC and LDL-C in both groups were significantly reduced（P〈0.05）and the level of HDL-C was significantly increased（P〈0.05）.Moreover,observation group had better clinical efficacy and larger changes of NIHSS scores relative to control group（P〈0.05）.No significant difference was found in term of the adverse incidence between two groups.ConclusionIntensive fluvastatin treatment can be safe and effective in treatment of progressive stroke,which should be worthy of clinical promotion.